Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up

摘要

Background: To evaluate long term outcomes in patients maintaining a NVP based regimen for more than 10 years. Materials and methods: Retrospective, multicenter, cohort study including virologically suppressed patients, currently receiving a NVP-based regimen that had been started at least 10 years previously. Demographic, clinical, and analytical variables were recorded. Results: Two hundred and seventy four subjects were included. Median (IQR) follow up was 17.1 (13.8-18.5) years. Dyslipidemia (29.9%), hypertension (11.4%) and diabetes (8%) were the most common reported co-morbidities. After a median of 17 years of follow-up we observed a significant increase in general health markers such as hemoglobin and CD4 cells (all p50<1000 copies/ml). Conclusions: Based on the extensive experience as well as a good tolerance and efficacy profile, NVP should be considered for treatment continuation in those patients already receiving this inexpensive generic drug.